Anbio Biotechnology Class A Ordinary Shares (NNNN) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Anbio Biotechnology Class A Ordinary Shares (US:NNNN), trading at 9.75. In 2025, Anbio Biotechnology Class A Ordinary Shares generated $9.76 Million in revenue and -$6.74 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Anbio Biotechnology Class A Ordinary Shares is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 9.75
- Recent Revenue (2025): $9.76 Million
- Free Cash Flow (2025): -$6.74 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.